National Research Corporation EBITDA 2011-2026 | NRC

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA National Research Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
30.2 M	41.2 M	45.9 M	46.7 M	50.6 M	43 M	48.6 M	40.7 M	38.8 M	35.4 M	30.6 M	32.1 M	28.5 M	27.4 M	23.8 M	18.6 M	17.5 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
50.6 M	17.5 M	35.3 M

Quarterly EBITDA National Research Corporation

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.74 M	9.93 M	3.33 M	10.1 M	-	9.53 M	10.4 M	10.2 M	-	11.5 M	10.9 M	10.4 M	-	12.4 M	12.8 M	13 M	-	13.1 M	12.2 M	12 M	-	13.9 M	10.7 M	12.6 M	-	11.6 M	11.6 M	12.1 M	-	10.6 M	9.08 M	10.2 M	-	8.25 M	9.59 M	11.1 M	-	8.42 M	8.11 M	8.97 M	-	7.62 M	7.39 M	6.84 M	-	8.11 M	7.24 M	9.34 M	-	6.94 M	6.46 M	8.17 M	-	6.8 M	6.43 M	7.32 M	-	5.51 M	5.07 M	6.94 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.9 M	3.33 M	9.4 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Fulgent Genetics FLGT	-49 M	$ 15.96	5.63 %	$ 483 M	USA
Burning Rock Biotech Limited BNR	-749 M	$ 16.76	1.09 %	$ 177 M	China
Castle Biosciences CSTL	-2.04 M	$ 19.83	3.07 %	$ 575 M	USA
Agilent Technologies A	1.67 B	$ 115.62	-2.55 %	$ 35.1 B	USA
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
Aspira Women's Health AWH	-7.8 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-12.3 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
CareDx, Inc CDNA	-15.8 M	$ 21.82	1.77 %	$ 1.16 B	USA
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	-25.8 M	-	-	$ 9.42 M	Israel
Lantheus Holdings LNTH	381 M	$ 93.06	2.26 %	$ 6.28 B	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Medpace Holdings MEDP	562 M	$ 424.0	-1.1 %	$ 12.2 B	USA
Co-Diagnostics CODX	-49.1 M	$ 2.53	31.09 %	$ 3.37 M	USA
Myriad Genetics MYGN	-334 M	$ 4.29	4.89 %	$ 397 M	USA
NeoGenomics NEO	-79.8 M	$ 8.96	-1.21 %	$ 1.15 B	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-518 M	-	0.12 %	$ 80.1 M	China
Natera NTRA	-524 M	$ 194.24	-11.64 %	$ 19.1 B	USA
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
Charles River Laboratories International CRL	428 M	$ 177.62	-2.23 %	$ 8.8 B	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
Koninklijke Philips N.V. PHG	2.55 B	$ 27.21	0.18 %	$ 25.8 B	Niderland
Exact Sciences Corporation EXAS	-81.4 M	-	-	$ 19.8 B	USA
Personalis PSNL	-78 M	$ 5.98	-0.17 %	$ 534 M	USA
Guardant Health GH	-398 M	$ 95.7	3.73 %	$ 12 B	USA
Senseonics Holdings SENS	-66.8 M	$ 5.03	-6.16 %	$ 210 M	USA
Soleno Therapeutics SLNO	11.4 M	$ 52.95	-	$ 2.69 B	USA
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
ICON Public Limited Company ICLR	1.59 B	$ 124.49	-0.41 %	$ 10.3 B	Irlanda
Illumina ILMN	-479 M	$ 141.88	2.29 %	$ 22.6 B	USA
Interpace Biosciences IDXG	4.51 M	$ 1.95	-2.5 %	$ 8.63 M	USA
QIAGEN N.V. QGEN	660 M	-	-	$ 10.6 B	Niderland
Trinity Biotech plc TRIB	-21.2 M	$ 0.61	2.52 %	$ 219 M	Irlanda
Twist Bioscience Corporation TWST	-111 M	$ 56.85	-2.89 %	$ 3.4 B	USA
Biomerica BMRA	-5.05 M	$ 2.15	-2.05 %	$ 4.94 M	USA
Thermo Fisher Scientific TMO	8.8 B	$ 465.0	-1.99 %	$ 175 B	USA
Laboratory Corporation of America Holdings LH	2.07 B	$ 254.12	-1.52 %	$ 21.1 B	USA
Celcuity CELC	-172 M	$ 131.06	0.27 %	$ 6.13 B	USA
Motus GI Holdings MOTS	-11.5 M	-	-34.28 %	$ 263 K	Israel
Waters Corporation WAT	359 M	$ 355.13	1.32 %	$ 21.1 B	USA
Neogen Corporation NEOG	-942 M	$ 9.05	-2.16 %	$ 1.96 B	USA
Quest Diagnostics Incorporated DGX	2.13 B	$ 187.39	-1.82 %	$ 20.8 B	USA